Most cited papers from Národný Onkologický Ústav

The most cited paper from Národný Onkologický Ústav is "Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study" (Heather S. Han et al., 2017), with 204 citations. Next come "A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer" (82) and "Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)" (74).

Showing 50 of 62 papers. Every paper with more than 4 citations is listed.

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.